Safety and Efficacy of Low-dose Pioglitazone (7.5 mg/day) vs. Standard-dose Pioglitazone (15 mg/day) in Japanese Women with Type 2 Diabetes Mellitus
| Autor: | Kazuwa Nakao, Kentaro Doi, Michika Shigemoto, Takafumi Majima, Atsushi Fukao, Chieko Takagi, Yasato Komatsu, Jerry Corners |
|---|---|
| Rok vydání: | 2006 |
| Předmět: |
Blood Glucose
medicine.medical_specialty medicine.drug_class Endocrinology Diabetes and Metabolism Peripheral edema Administration Oral Blood Pressure Weight Gain Gastroenterology Group B Endocrinology Japan Internal medicine Edema medicine Humans Thiazolidinedione Triglycerides Aged Glycated Hemoglobin Dose-Response Relationship Drug Pioglitazone business.industry Incidence Cholesterol HDL Type 2 Diabetes Mellitus Cholesterol LDL Fasting Middle Aged Cholesterol Treatment Outcome Diabetes Mellitus Type 2 Metabolic control analysis Female Thiazolidinediones medicine.symptom business Weight gain medicine.drug |
| Zdroj: | Endocrine Journal. 53:325-330 |
| ISSN: | 1348-4540 0918-8959 |
| DOI: | 10.1507/endocrj.k05-067 |
| Popis: | It is well known that pioglitazone, a potent thiazolidinedione, improves metabolic control. However, weight gain or peripheral edema may be of major clinical concern when using this agent. The purpose of our study was to prospectively evaluate the effects of low-dose pioglitazone (7.5 mg/day) on metabolic control, weight gain and the incidence of edema compared with a standard dose of pioglitazone (15.0 mg/day) in patients with type 2 diabetes mellitus (T2DM). Ninety-five Japanese female patients (mean age 58.4 +/- 10.4 years) with newly diagnosed T2DM were selected for this study. They were randomly divided into the following 2 groups according to therapy regimens, and examined every month for 6 months after diagnosis. Group A consisted of 54 patients treated with low-dose pioglitazone orally; Group B, the control-group, consisted of 41 patients treated with standard-dose pioglitazone orally. The incidence of peripheral edema was significantly much lower in group A (2/54) than in group B (11/41) (p = 0.0014). In addition, % change of body weight during the 6-month treatment in group A was significantly less than that in group B (p < 0.0001). On the other hand, the % change of biochemical parameters including HbA1c did not differ significantly between group A and group B, although glucose and lipid control significantly improved from baseline in both groups. Our results demonstrate the safety and efficacy of low-dose pioglitazone, suggesting that it could be another good choice of treatment for Japanese women with T2DM. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|